Elena Shagisultanova

Also affiliated with University of Colorado Anschutz Medical Campus, University of Colorado Denver

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “Safety and Efficacy of Tucatinib, Letrozole, and Palbociclib in Patients with Previously Treated HR+/HER2+ Breast Cancer”.

Safety and Efficacy of Tucatinib, Letrozole, and Palbociclib in Patients with Previously Treated HR+/HER2+ Breast Cancer

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-23-0117

N/A

0.603DataRank · unranked

12 citations

William J. Gradishar, Ursa Brown-Glaberman, Pavani Chalasani, Andrew Brenner, Alison Stopeck +8 more

Triple Targeting of Breast Tumors Driven by Hormonal Receptors and HER2

Molecular Cancer Therapeutics(2021)10.1158/1535-7163.mct-21-0098

N/A

0DataRank · unranked

14 citations

Lyndsey S. Crump, Michelle Borakove, Jessica Hall, Aryana R. Rasti, Benjamin A Harrison +4 more

Sequential Therapy With HER2 Tyrosine Kinase Inhibitors in Patients With HER2-Positive Metastatic Breast Cancer

Clinical Breast Cancer(2025)10.1016/j.clbc.2025.06.004

N/A

0DataRank · unranked

3 citations

Hannah Parris, Long Liu, Stephanie Giangiuli, Dexiang Gao, Jennifer R. Diamond +4 more